← boardnext 2026-08-15next 2027-03
PMVP
PMV Pharmaceuticals, Incdistress 3/10 · well-funded / low risk$1.39+4%today-23% from 52w high
Oncology 1
Lead: platinum-resistant/refractory ovarian cancer · target PD-1 · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$94M
Runway
1.3 yrs
Shares 1y
+1%
Price & events
+21.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.1%
1D
+6.5%
1W
+14.5%
1M
-3.1%
3M
+18.4%
6M
+2.6%
1Y
-14.0%
2Y
-96.2%
5Y
-97.2%
All
Overview
- Market Cap
- $73.86M
- Volume
- 42.87K
- 52 Week Range
- $1.02 – $1.80
- Total Shares
- 53.33M
- Float Shares
- 43.14M
- Short %
- 5.65%
- % Held by Insiders
- 3.35%
- % Held by Institutions
- 67.75%
- RVOL
- 0.14x
- Beta
- 1.33
Pipeline stages · 2 programs
rezatapopt, pembrolizumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg table
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-15 Estimated 50% readout ~2026-09-29 | Phase 1/2 | rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | recruiting |
| 2027-03 Estimated 50% readout ~2027-03-31 | Phase 1 | metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg table | TP53 Y220C Mutation, Advanced Solid Tumors | — | recruiting |
Catalyst news & presentations · 2
- 1Q2027Guided 70%regulatory submissionFiled (NDA/BLA)rezatapopt · NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancerSEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $4 (+189% upside) · 4 analysts
- 2026-05-13OppenheimerOutperform
- 2025-03-20HC Wainwright & Co.Buy
- 2024-08-20HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-142026 MLB All-Star Game: Expert picks for Midsummer Classic MVP - CBS Sports
- 2026-07-132026 MLB awards tracker: Odds for MVP, Cy Young, Rookie of the Year - ESPN
- 2026-07-132026 WNBA MVP Odds: A’ja Wilson, Paige Bueckers Lead Way; Caitlin Clark Falls to 10/1 - Sports Illustrated
- 2026-07-12A long way from family farm, Rays 19-year-old catcher wins Futures Game MVP - MLB.com
- 2026-07-12Canadian Nathan Flewelling named MVP of MLB All-Star Futures Game - Sportsnet.ca
- 2026-07-10PMV Pharmaceuticals (PMVP) Holds Steady Near Support as Consolidation Continues - Straddle Setup - DonanımHaber
- 2026-07-10ArrowMark Colorado Holdings (PMVP) holds 3.67% stake in PMV Pharmaceuticals - Stock Titan
- 2026-07-08PMVP Assumes Buy Rating by Ladenburg Thalmann -- Price Target Se - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.